# CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy

> **NCT07443826** · PHASE1,PHASE2 · RECRUITING · sponsor: **Unlimited Biotechnology LLC** · enrollment: 12 (estimated)

## Conditions studied

- Age-related Muscle Decline

## Interventions

- **GENETIC:** AAV9-Follistatin gene therapy
- **GENETIC:** VEGF Plasmid

## Key facts

- **NCT ID:** NCT07443826
- **Lead sponsor:** Unlimited Biotechnology LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07443826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07443826, "CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07443826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*